{
  "source": "PA-Notification-Berinert.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1011-12\nProgram Prior Authorization/Notification\nMedication Berinert® (C1 esterase inhibitor, human)\nP&T Approval Date 11/2012, 11/2013, 8/2014, 8/2015, 7/2016, 7/2017, 7/2018, 7/2019,\n7/2020, 7/2021, 7/2022, 7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nBerinert is a plasma-derived C1 esterase inhibitor (human) indicated for the treatment of acute\nabdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adult and pediatric\npatients. The safety and efficacy of Berinert for prophylactic therapy has not been established.1\n2. Coverage Criteriaa:\nA. Berinert will be approved based on all of the following criteria:\n1. Diagnosis of hereditary angioedema (HAE)\n-AND-\n2. For the treatment of acute HAE attacks\n-AND-\n3. Not used in combination with other products indicated for acute HAE attacks (e.g.,\nFirazyr, Kalbitor or Ruconest)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n© 2024 UnitedHealthcare Services, Inc.\n1\n3. References:\n1. Berinert [package insert]. Kankakee, IL: CSL Behring LLC; September 2021.\nProgram Prior Authorization/Notification - Berinert® (C1 esterase inhibitor,\nhuman)\nChange Control\n11/2013 Annual review. Removed requirement for Type I or II HAE. Changed\nauthorization duration from 12 months to 60 months.\n8/2014 Annual review. Added an additional criterion that does not allow\ncombination use with other HAE ac",
    " requirement for Type I or II HAE. Changed\nauthorization duration from 12 months to 60 months.\n8/2014 Annual review. Added an additional criterion that does not allow\ncombination use with other HAE acute treatments. Decreased\nauthorization from 60 months to 12 months. Updated Background and\nReferences.\n8/2015 Annual Review. Updated references.\n7/2016 Annual Review with no changes to the coverage criteria. Updated\nbackground and references.\n7/2017 Annual review with no changes to the coverage criteria. Updated\nbackground and references.\n7/2018 Annual review with no changes to the coverage criteria. Updated\nreferences.\n7/2019 Annual review with no changes to coverage criteria. Updated\nreferences.\n7/2020 Annual review with no changes to coverage criteria.\n7/2021 Annual review with no changes to coverage criteria. Updated\nreferences.\n7/2022 Annual review with no changes to coverage criteria. Added state\nmandate footnote. Updated reference.\n7/2023 Annual review. Revised wording of criteria without change to clinical\nintent.\n7/2024 Annual review with no changes to coverage criteria.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}